115 - Bacterial Persisters and Nonculturable Forms: Basic Biology and Therapeutic Susceptibility

10/4/2019

10:30 AM - 11:45 AM

Room: Walter E. Washington Convention Center, 152 AB

MOC Credit: Maximum of 1.25 hours of MOC Credit
CME Credit: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE Credit: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: 0221-9999-19-366-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

discuss new models for the discovery of compounds against MRSA
describe new approaches for drug discovery
discuss the challenges associated with the discovery of compounds with activity against persister cells

Presentations:

10:30 AM - 10:55 AM
932 - Therapeutic targeting of S. aureus persisters
Eleftherios Mylonakis, MD, PhD – Brown University
10:55 AM - 11:20 AM
933 - Role of Cholera Biofilms in the infection Lifecyle
Fitnat Yildiz – University of California, Santa Cruz
11:20 AM - 11:45 AM
934 - Differentially detectable Mycobacterium tuberculosis in treatment resistance and relapse
Kohta Saito, MD, MPH – Weill Cornell Medicine

Moderator(s)

Michael Glickman, MD, FIDSA, FAAM

Member, Attending Physician
Memorial Sloan Kettering
New York, New York

Disclosure: Takeda: Consultant, Independent Contractor
Vedanta Biosciences: Advisory Board, Consultant, Independent Contractor

Speaker(s)

Eleftherios Mylonakis, MD, PhD

Professor of Medicine, Professor of Molecular Microbiology and Immunology
Brown University
Providence, Rhode Island

Disclosure: Sanofi-Pasteur: Grant/Research Support
T2 Biosystems: Grant/Research Support
Kohta Saito, MD, MPH

Instructor
Weill Cornell Medicine
New York, NY

Disclosure: Nothing to disclose
FY

Fitnat Yildiz

University of California, Santa Cruz
Santa Cruz, CA

Disclosure: Nothing to disclose